Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

First International Summit on Interventional Pharmacoeconomics

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Welcome and Introduction to Vi3C

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Jul

Today In Oncology

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Related Videos

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Welcome and Introduction to Vi3C

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Breast Cancer Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease

Single-Fraction SBRT in Localized Prostate Cancer

Paving New ROADS in the Treatment of Brain Metastases With Implanted Tile-Based Radiation Therapy

FDA Approves Immunotherapy to Reduce Chronic GVHD in Patients Undergoing Stem Cell Transplant

Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma